Trial Profile
A retrospective study evaluating efficacy and safety of intravitreal ziv-aflibercept for the treatment of choroidal neovascularisation associated with conditions other than age-related macular degeneration
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 21 Sep 2017
Price :
$35
*
At a glance
- Drugs Aflibercept (Primary)
- Indications Choroidal neovascularisation
- Focus Therapeutic Use
- 21 Sep 2017 New trial record
- 01 Sep 2017 Results published in the British Journal of Ophthalmology